The 20 Best Eccrine Porocarcinoma Doctors Near Me in Ann Arbor, MI

Dr. Kelly Harms, MD, PhD, is a faculty member in the Department of Dermatology at the University of Michigan and the director of our Multi-disciplinary Cutaneous Oncology clinic. She provides patient care in our Cutaneous Surgery and Oncology clinical programs, including the Mohs surgery clinic and multidisciplinary melanoma and cutaneous oncology clinics located within the U-M Rogel Cancer Center. Dr. Harms is a board-certified dermatologist and ACGME Fellowship-trained Mohs Surgeon, with specialized training and expertise in treating high-risk skin cancer.Dr. Harms joined the Dermatology faculty in 2014, upon completing her ACGME procedural dermatology fellowship, with advanced training in melanoma and cutaneous surgery and oncology at the Rogel Cancer Center. Her clinical work is focused on Mohs surgery and associated reconstruction, as well as the complex management of patients seen within our Multidisciplinary Melanoma and Merkel Cell Programs.Dr. Harms received her medical degree from the University of Alabama School of Medicine and her Ph.D. degree from the Medical Scientist Training Program in the Department of Cell Biology at the University of Alabama at Birmingham. She completed her internship in the Department of Internal Medicine, University of Michigan Hospitals. She completed her dermatology residency, post-doctoral research training, and procedural dermatology fellowship in the Department of Dermatology, University of Michigan Medical School. Her clinical research is focused on skin cancer biology and epidemiology, and therapy. Dr. Harms is rated as a Distinguished provider by MediFind in the treatment of Eccrine Porocarcinoma. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Merkel Cell Carcinoma, Melanoma, Eccrine Porocarcinoma, and Basal Cell Skin Cancer. Dr. Harms is board certified in Dermatology and Micrographic Dermatologic Surgery.

Dr. Christopher Bichakjian is professor of dermatology and chair of the Department of Dermatology at the University of Michigan Medical School.Dr. Bichakjian is a foremost expert in the field of cutaneous surgery and oncology. He has a special interest in Merkel cell carcinoma and established one of the first multidisciplinary programs in the world for this rare skin cancer in 2006. He has presented over 100 national and international invited lectures and visiting professorships, and authored or co-authored nearly 90 peer-reviewed publications with a primary focus on cutaneous oncology.Dr. Bichakjian received his medical degree from Radboud University in The Netherlands. After relocating to the US, he completed residency in dermatology and fellowship in micrographic surgery and cutaneous oncology at Michigan Medicine. He subsequently practiced Mohs surgery in private practice and served as adjunct faculty at Weill Medical College at Cornell University in New York City.In 2004, Dr. Bichakjian was recruited back to Ann Arbor to join the faculty in the Department of Dermatology at Michigan Medicine. He served as director of the UM Multidisciplinary Merkel Cell Carcinoma Program for more than a decade (2006-2017), In addition, he served as chief of the Division of Cutaneous Surgery and Oncology and as director of the Multidisciplinary Melanoma Program in the Rogel Cancer Center from 2017-2020. Dr. Bichakjian is rated as a Distinguished provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Merkel Cell Carcinoma, Basal Cell Skin Cancer, Melanoma, and Eccrine Porocarcinoma. Dr. Bichakjian is board certified in Dermatology and Micrographic Dermatologic Surgery.

After receiving my M.D. and Ph.D. at the University of Alabama at Birmingham, I came to the University of Michigan for residency training in Anatomic Pathology. During my residency and subsequent Dermatopathology fellowship, I became interested in mechanistic studies of cutaneous and soft-tissue malignancies. Upon completion of my fellowship in June 2012, I accepted a faculty position at UMHS with joint appointments in the Departments of Dermatology and Pathology, in which I continue to investigate molecular events in the pathogenesis of Merkel cell carcinoma and other cutaneous malignancies, while maintaining clinical effort in dermatopathology and molecular dermatopathology. Dr. Harms is rated as a Distinguished provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Merkel Cell Carcinoma, Tieche-Jadassohn Nevus, Melanoma, and Sebaceous Adenoma. Dr. Harms is board certified in Pathology-Anatomic and Dermatopathology.

Scott Mclean is an Otolaryngologist and a Plastic Surgeon practicing medicine in Ann Arbor, Michigan. Dr. Mclean is rated as a Distinguished provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Teratocarcinosarcoma, Sinus Cancer, Tissue Biopsy, and Laryngectomy. Dr. Mclean is board certified in Otolaryngology-Head & Neck Surgery.

Dr. Elisabeth (Beth) Pedersen is an Assistant Professor in the Department of Dermatology at the University of Michigan. She is a board-certified dermatologist and provides patient care within our Multidisciplinary Cutaneous Oncology Clinic at the Taubman Center and Rogel Cancer Center.Dr. Pedersen specializes in advanced and high-risk skin cancer. She sees patients with Merkel cell carcinoma, melanoma, and advanced basal cell carcinoma. She also has a particular interest in rare skin cancers including dermatofibrosarcoma protuberans and other skin sarcomas.Dr. Pedersen received her Doctor of Medicine (MD) and Doctor of Philosophy (PhD) degrees through at the University of Michigan. She completed dermatology residency and postdoctoral research training at the University of Michigan Medical School. In addition to her clinical practice, she performs laboratory research focused on understanding the molecular and cellular biology of skin cancers, with the goal of identifying new strategies for cancer treatment. Dr. Pedersen is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Merkel Cell Carcinoma, Eccrine Porocarcinoma, Melanoma, and Sunburn.

Jeffrey H. Kozlow, MD, serves as a Clinical Associate Professor in the Section of Plastic and Reconstructive Surgery at the University of Michigan School of Medicine. A native of Southeastern Michigan, Dr. Kozlow received his Bachelors of Arts in Psychology and Chemistry from Cornell University. He graduated from Johns Hopkins University School of Medicine for his M.D. degree. He underwent Plastic Surgery Residency training at the University of Michigan followed by an additional one-year fellowship in Microvascular Reconstructive Surgery at the University of Texas – MD Anderson Cancer Center. He has returned to the University of Michigan joining the faculty in 2011. Clinical Specialization: Dr. Kozlow is clinically focused on the reconstruction of oncologic and traumatic defects. His microsurgical training allows him to perform abdominally-based breast reconstruction including DIEP and muscle-sparing TRAM flaps. He partners with members of the University of Michigan Rogel Cancer Center to provide an integrated and multi-disciplinary reconstruction for complex defects including the extremities and pelvis. His goal is to perform reconstructions that optimize the function and form that can be lost following the surgical removal of tumors. He also treats patients with primary cutaneous malignancies including melanoma and other skin cancers. Dr. Kozlow is rated as a Distinguished provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Eccrine Porocarcinoma, Melanoma, Breast Cancer, Mastectomy, and Lymphadenectomy. Dr. Kozlow is board certified in Plastic Surgery.

Dr. Jennifer Schwartz received her medical degree from Northwestern University Medical School and completed her internship in internal medicine at Northwestern Medical Center in Chicago. She completed her dermatology residency at the University of Michigan Department of Dermatology and two years of specialty training in melanoma at the U-M Rogel Cancer Center.Additionally, she completed advanced specialty training in cutaneous surgery treatment of benign and malignant lesions at the University of Michigan. In 1999, Dr. Schwartz became a faculty member of the Melanoma and Cutaneous Oncology and Surgery Program. Dr. Schwartz is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Melanoma, Eccrine Porocarcinoma, Squamous Cell Skin Carcinoma, and Merkel Cell Carcinoma. Dr. Schwartz is board certified in Dermatology.

"Dr. Michael J. Davis is a Clinical Assistant Professor and board-certified Mohs surgeon and dermatologist in the Michigan Medicine Department of Dermatology. He provides expert care for patients with high-risk and advanced skin cancer in the Cutaneous Surgery and Oncology outpatient clinic at the UM Rogel Cancer Center and is a member of the multidisciplinary cutaneous oncology program.Dr. Davis graduated from the School of Medicine at Emory University, completed a dermatology residency at Dartmouth University, and pursued a Micrographic Surgery and Dermatologic Oncology clinical fellowship at Scripps Health in La Jolla, California. He completed a one-year Cutaneous Oncology Research Fellowship at Memorial Sloan Kettering Cancer Center, where he also served as an instructor of dermatology and interim assistant director of the Mohs lab for the Dermatology Service.Dr. Davis’s clinical and scholarly interests center on cutaneous surgery and oncology, with an emphasis on Mohs histopathology. He has co-authored seven chapters for the ""Laboratory Manual for Mohs Micrographic Surgery Frozen Tissue Processing,"" a comprehensive reference on the Mohs tissue processing technique (Springer, April 2024). He is an active member of the American Academy of Dermatology, the American Society for Dermatologic Surgery, the American College of Mohs Surgery, and the International Immunosuppression and Transplant Skin Cancer Collaborative.". Dr. Davis is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Melanoma, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Davis is board certified in Micrographic Dermatologic Surgery and Dermatology.

Dr. Tejasvi received his medical degree from Karnataka Institute of Medical Sciences, India. He completed residency-training program and worked as senior resident in Dermatology and Venereology, from All India Institute of Medical Sciences, New Delhi, India. He completed post-doctoral training in genetics of psoriasis under the direction of Drs. R.P.Nair and James T. Elder at the University of Michigan, Department of Dermatology in Ann Arbor.Dr. Tejasvi's primary research interest is translational genetics, epigenetics in psoriasis and pharmacogenetics that involves application of genetic information to predict response to therapies. Dr. Tejasvi is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Lymphomatoid Papulosis.

Scott Regenbogen, MD, MPH is a Professor of Surgery and Division Chief of Colorectal Surgery. He graduated from Princeton University with an A.B. in psychology, and received his M.D. degree from the University of California, San Francisco. He completed General Surgery residency at the Massachusetts General Hospital, including three years as a Postdoctoral Fellow in Health Services Research, and was awarded a Master’s in Public Health from the Harvard School of Public Health. He then completed fellowship training in Colon and Rectal Surgery at the Lahey Clinic, and joined the faculty of the University of Michigan in 2011.Clinical SpecializationDr. Regenbogen's clinical practice includes the evaluation and management of benign and neoplastic diseases of the small bowel, colon, rectum, and anus. He has a particular interest in the use of laparoscopic techniques for the management of colorectal cancer, diverticular disease and inflammatory bowel disease. Dr. Regenbogen is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Anal Cancer, Ileostomy, and Hernia Surgery. Dr. Regenbogen is board certified in Surgery and Colon & Rectal Surgery.

John C. Byrn, M.D is a Clinical Professor of Surgery in the Division of Colorectal Surgery. He graduated from Hope College with a B.A. in Chemistry and received his MD degree from the University of Illinois-Chicago College of Medicine. He trained in general surgery at Mount Sinai School of Medicine in New York, NY. Dr. Byrn went on for his Colon and Rectal residency at the Cleveland Clinic, Cleveland, OH. Dr. Byrn was a Clinical Assistant and Associate Professor of Surgery at the University of Iowa Hospitals and Clinics from 2009-2015 and served as the Chief of the Section of Colorectal Surgery from 2013-2105. Dr. Byrn is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Rectal Prolapse, Familial Colorectal Cancer, Ileostomy, and Colostomy. Dr. Byrn is board certified in Surgery and Colon & Rectal Surgery.

Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology.

Dr. Lesly Dossett, MD, MPH, is the Maud T. Lane Research Professor for Cancer Quality Improvement and Chief of the Division of Surgical Oncology at the University of Michigan. Dr. Dossett earned her medical degree from Vanderbilt University School of Medicine in 2003, having attended on a United States Navy Health Professions Scholarship. She completed her general surgery residency at Vanderbilt University in 2010, which included a health services research fellowship and completion of an MPH. After residency, Dr. Dossett served on active duty with the United States Navy in several roles stateside and overseas, including completing two deployments supporting combat operations in Afghanistan. After leaving the Navy in 2014, Dr. Dossett completed a clinical fellowship in Complex General Surgical Oncology at Moffitt Cancer Center and joined the faculty of the University of Michigan in 2016.Dr. Dossett specializes in treating patients with melanoma, soft tissue sarcoma, and breast cancer. Her research leverages implementation science frameworks and behavioral strategies to improve healthcare value. As co-director of the Michigan Program for Value Enhancement (MPrOVE), she works to translate value-based research findings into practice at Michigan Medicine and then scale those strategies more broadly to hospitals and healthcare systems. She is a principal investigator for R01s funded by the National Cancer Institute (NCI) and the Agency for Healthcare Research and Quality (AHRQ). She serves as a mentor on several federally funded training grants and career development awards.Dr. Dossett is an active member of several national societies. She serves as an officer in the Association for Academic Surgeons (AAS) and in the executive leadership of the American College of Surgeons (ACS) Cancer Research Program (CRP) and the Surgical Outcomes Club.Clinical Specialization:Dr. Dossett’s clinical focus is on melanoma and non-melanoma skin cancers, sarcoma, and breast cancer. She has expertise in locally and regionally advanced melanoma, breast angiosarcoma, retroperitoneal and pelvic sarcoma, breast conservation therapy, and skin and nipple sparing mastectomy. Dr. Dossett is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. She is also highly rated in 30 other conditions, according to our data. Her clinical expertise encompasses Retroperitoneal Liposarcoma, Melanoma, Desmoplastic Small Round Cell Tumor, Mastectomy, and Lymphadenectomy. Dr. Dossett is board certified in Surgery and Complex General Surgical Oncology.

Dr. May Chan obtained her medical degree from the State University of New York at Buffalo and was a Howard Hughes Research Scholar in 2005-2006. She completed residency training in Anatomic Pathology at Beth Israel Deaconess Medical Center in Boston, followed by a Dermatopathology fellowship at Harvard. She joined the University of Michigan in 2011 and is now a Professor of Pathology and Dermatology. She is the Interim Section Head for Dermatopathology, the Program Director for the Dermatopathology Fellowship, and the Medical Director of the Immunohistochemistry Laboratory. She also serves on the Test Development and Advisory Committee of the American Board of Pathology.Dr. Chan is an editorial board member of Modern Pathology and Journal of Cutaneous Pathology. She has a broad research interest in the areas of inflammatory skin diseases, melanocytic lesions, cutaneous adnexal neoplasms, and immunohistochemistry. She is the author/co-author of over 90 peer-reviewed publications and the book, Handbook of Direct Immunofluorescence: A Pattern-based Approach to Skin and Mucosal Biopsies.Dr. Chan is board certified in Anatomic Pathology and Dermatopathology. In addition to her primary role as a dermatopathologist, Dr. Chan retains her interest in surgical pathology including interpretation of head and neck, soft tissue, pulmonary, and endocrine cases, as well as intraoperative frozen sections. Over the years she has been invited to speak at national and international meetings hosted by the United States and Canadian Academy of Pathology (USCAP), the American Society of Dermatopathology (ASDP), the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), the American Academy of Dermatology (AAD), the European Nail Society, and Dermpedia. Dr. Chan is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Melanoma, Basal Cell Skin Cancer, Sebaceous Adenoma, and Squamous Cell Skin Carcinoma.

Dr. Angeles is an Associate Professor with Tenure of Surgery, Associate Professor of Dermatology, and Faculty Member in the Cancer Biology PhD Program at the University of Michigan in the Division of Surgical Oncology. She earned her medical degree at Tufts University School of Medicine. She completed general surgery residency at New York Presbyterian-Weill Cornell Medical Center. While in residency she completed a two-year basic/translational science Surgical Oncology Research Fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) focusing on the molecular biology and novel therapeutics for sarcoma. After residency, Dr. Angeles returned to MSKCC and completed a clinical Complex Surgical Oncology Fellowship. Dr. Angeles is board-certified in both General Surgery and Complex General Surgical Oncology. She is the Director of the Regional Cancer Therapies Clinic at University of Michigan/Rogel Cancer Center. Dr. Angeles is a nationally recognized surgeon-scientist dedicated to advancing cancer care through innovative research and compassionate patient care. As the lead investigator for multiple clinical trials at the Rogel Cancer Center, she is at the forefront of developing new treatments for melanoma and sarcoma. Her laboratory studies the immune system’s role in fighting cancer, with a special focus on how resident memory T cells can help create long-lasting protection against tumors. By combining basic science and translational research, Dr. Angeles and her team are working to transform discoveries in the lab into effective new therapies for patients. Dr. Angeles’s research has been supported by the American Cancer Society, the Melanoma Research Alliance, the Society of Surgical Oncology, and the National Institutes of Health’s National Cancer Institute (NCI-NIH).Committed to excellence in both science and patient care, Dr. Angeles is a Fellow of the American College of Surgeons, a Fellow of the Society of Surgical Oncology, and an active member of professional societies including the American Society of Clinical Oncology (ASCO), the Society of Surgical Oncology (SSO), the Connective Tissue Oncology Society (CTOS), and the Society for Immunotherapy of Cancer (SITC). She also serves as Chair of the Society of Surgical Oncology's Research Committee, helping to shape the future of cancer research and treatment.Clinical Specialization:Dr. Angeles is a board-certified surgical oncologist whose clinical practice focuses on patients with soft tissue cancers including sarcoma, melanoma, and non-melanoma cutaneous malignancies. Dr. Angeles cares for patients in a robust multidisciplinary fashion and provides education and counseling to her patients in order to allow shared decision making for the surgical management of their disease. Dr. Angeles is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Melanoma, Splenectomy, and Nephrectomy. Dr. Angeles is board certified in Surgery and Complex General Surgical Oncology.

Dr. Uppal is a board-certified Gynecologic Oncologist and Division Chief for the Gynecology Oncology service at the University of Michigan. He is also the Director of Gynecologic Oncology Initiatives at the Michigan Oncology Quality Consortium (MOQC) - a statewide quality improvement network. Dr. Uppal received his medical degree from the All India Institute of Medical Sciences (AIIMS) in New Delhi, India. He completed his Obstetrics and Gynecology residency at Temple University Hospital in Philadelphia and a fellowship in Gynecology Oncology at the University of Wisconsin in Madison, Wisconsin. He joined the faculty of the University of Michigan in 2014. Dr. Uppal also holds a Master in Business Administration (MBA) from the University of the Michigan Stephen M. Ross School of Business.Dr. Uppal has been in clinical practice for over ten years and is involved in many Quality Improvement Projects in the Division of Gynecologic Oncology, nationally and across Michigan. Widely acknowledged as a thought leader in Gynecology Oncology and quality-of-care, he has authored over 75 peer-reviewed manuscripts and instituted changes in the health system to improve outcomes after surgery, reduce the cost of care and implemented patient-centered care delivery systems. Dr. Uppal is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy. Dr. Uppal is board certified in Gynecologic Oncology and Obstetrics & Gynecology.

Dr. Hansen is a graduate of the University of Michigan. She then completed her medical degree at the Kirksville College of Osteopathic Medicine and residency training at the University of Iowa Hospitals and Clinics. She completed her gynecologic oncology fellowship at MD Anderson Cancer Center. She joined the faculty as an assistant professor in 2018. She serves on national committees for both the Society of Gynecologic Oncology and NRG Oncology. She is the principal investigator for Gynecologic Oncology Group (GOG) and industry-sponsored clinical research trials available at the University of Michigan. Dr. Siedel is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Malignant Mixed Mullerian Tumor, and Testicular Yolk Sac Tumor.

Michael Englesbe, MD, FACS is the Cyrenus G Darling Sr M.D. and Cyrenus G Darling Jr M.D. Professor of Surgery at the University of Michigan in the Section of Transplantation Surgery. Dr. Englesbe received his undergraduate degree at Yale University in New Haven, Connecticut in 1993. He went on to obtain his medical degree in 1997 from the Robert Wood Johnson Medical School and completed his general surgery residency at the University of Michigan Health System in 2004. From 2000 to 2002, Dr. Englesbe did a surgical research post-doctoral fellowship at the University of Washington Medical Center in Seattle, Washington. He does kidney and liver transplantation in adults and children. He has a specific expertise in portal hypertension in children and adults.Education Focus:Dr. Englesbe particularly enjoys working with undergraduate students, medical students, and young physician trainees. He serves as the Department of Surgery Vice Chair for Resident Mentorship and the University of Michigan Medical School Capstone Curriculum Director.Clinical Specialization:Dr. Englesbe specializes in kidney and liver transplantation in adults and children. He has a specific expertise in portal hypertension in children and adults. Dr. Englesbe is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Hernia, Liver Failure, End-Stage Renal Disease (ESRD), Liver Transplant, and Kidney Transplant. Dr. Englesbe is board certified in Surgery.

Scott Schuetze is an Oncologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Schuetze is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma.

Dr. Geoffrey Siegel is a Michigan native who received his Medical Doctorate Degree at the Detroit Medical Center and his residency in Orthopaedic Surgery at Wayne State University. After finishing his fellowship in Orthopaedic Oncology at Vanderbilt University Medical Center in Nashville, Tennessee, he joined the Department of Orthopaedic Surgery at the University of Michigan as Clinical Assistant Professor.Dr. Siegel's clinical interests are in the treatment of benign and malignant disease, both metastatic as well as primary bone cancer in adults and children. His surgical interests include limb salvage and complex musculoskeletal reconstruction. He enjoys both resident and community physician education in the field of Musculoskeletal Oncology. Dr. Siegel is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Bone Tumor, Chondrosarcoma, Epithelioid Sarcoma, and Hip Replacement. Dr. Siegel is board certified in Orthopedic Sports Medicine and Orthopedic Surgery.